Understanding Preferences for Disease-Modifying Drugs in Osteoarthritis
نویسندگان
چکیده
منابع مشابه
New targets for disease modifying osteoarthritis drugs: chondrogenesis and Runx1.
Osteoarthritis (OA) has recently been defined as a ‘whole joint’ disease with pathological changes in all tissues, including articular cartilage degradation, subchondral bone thickening, osteophyte formation, synovial inflammation and degeneration of ligaments, and, in the knee, the menisci. OA is a chronic musculoskeletal disease that leads to pain and severe impairment of mobility. OA is the ...
متن کاملPatient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis.
OBJECTIVES With an increasing number of disease-modifying treatments (DMTs) for multiple sclerosis (MS), patient preferences will gain importance in the decision-making process. We assessed patients' implicit preferences for oral versus parenteral DMTs and identified factors influencing patients' treatment preference. METHODS Patients with relapsing-remitting MS (n = 156) completed a question...
متن کاملDisease-modifying drugs in Alzheimer’s disease
Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder and the most common cause of dementia. The early stages of AD are characterized by short-term memory loss. Once the disease progresses, patients experience difficulties in sense of direction, oral communication, calculation, ability to learn, and cognitive thinking. The median duration of the disease is 10 years. The pathol...
متن کاملDiscoidin Domain Receptor 2 as a Potential Therapeutic Target for Development of Disease-Modifying Osteoarthritis Drugs.
Osteoarthritis (OA) is the most common form of arthritis disorders, but the identification of therapeutic targets to effectively prevent OA has been increasingly difficult. The goal of this investigation is to provide experimental evidence that discoidin domain receptor 2 (DDR2) may be an ideal target for the development of disease-modifying OA drugs. Ddr2 was conditionally deleted from articul...
متن کاملBiologic Disease-Modifying Antirheumatic Drugs
1. Distinguish between biologic DMARD use and nonbiologic DMARD use in the treatment of rheumatoid arthritis (RA). 2. Assess the differences between classes of biologic disease-modifying antirheumatic drug (DMARD) therapy. 3. Based on individual patient characteristics, construct a treatment and monitoring plan for a patient with RA and, when appropriate, include biologic DMARD therapy. 4. Just...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arthritis Care & Research
سال: 2014
ISSN: 2151-464X
DOI: 10.1002/acr.22280